Amino Acid PET Imaging to Assess the Efficacy of IDH Inhibitor Treatments for Patients With Refractory IDH Mutated Gliomas
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy
研究概览
简要总结
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas
详细描述
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas In fact, this study will allow us to assess, using Rano 1.0 criteria for PET and Rano 2.0 criteria for MRI, which of the two examinations is most effective in assessing the efficacy of anti-IDH treatment patients with refractory IDH-mutated gliomas.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024
排除标准
- •Individuals who have objected to the use of their data
结局指标
主要结局
Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy
时间窗: one day
Comparison between early therapeutic response according to RANO 1.0 and RANO 2.0 PET criteria and tumor progression at 6 months
次要结局
- Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy for the identification of lesions(one day)
研究者
Antoine VERGER
Principal investigator
Central Hospital, Nancy, France